Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Romanoff

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
JAMA Neurology|October 9, 2023
Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or DementiaGil D Rabinovici, Maria C Carrillo, Charles Apgar, et al.
JAMA Neurology|October 3, 2022
Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort StudyConsuelo H Wilkins, Charles C Windon, Peggye Dilworth-Anderson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumCharles C Windon, Constantine Gatsonis, Justin Romanoff, et al.
JAMA Oncology|October 16, 2025
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ: A Randomized Clinical TrialSeema A Khan, Justin Romanoff, Constantine Gatsonis, et al.
Future Oncology (London, England)|October 6, 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, et al.
JAMA Network Open|July 3, 2025
Quality of Life Among Patients With Ductal Carcinoma In SituVictoria J Dunsmore, Bradley S Snyder, Ilana F Gareen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 29, 2025
Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS StudyCharles C Windon, Constantine Gatsonis, Maria C Carrillo, et al.
Radiology|September 5, 2018
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter TrialSavannah C Partridge, Zheng Zhang, David C Newitt, et al.
JAMA Network Open|May 10, 2022
Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)Soudabeh Fazeli, Bradley S Snyder, Ilana F Gareen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2019
Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702)Habib Rahbar, Zheng Zhang, Thomas L Chenevert, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
JAMA Neurology|October 9, 2023
Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or DementiaGil D Rabinovici, Maria C Carrillo, Charles Apgar, et al.
JAMA Neurology|October 3, 2022
Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort StudyConsuelo H Wilkins, Charles C Windon, Peggye Dilworth-Anderson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumCharles C Windon, Constantine Gatsonis, Justin Romanoff, et al.
JAMA Oncology|October 16, 2025
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ: A Randomized Clinical TrialSeema A Khan, Justin Romanoff, Constantine Gatsonis, et al.
Future Oncology (London, England)|October 6, 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, et al.
JAMA Network Open|July 3, 2025
Quality of Life Among Patients With Ductal Carcinoma In SituVictoria J Dunsmore, Bradley S Snyder, Ilana F Gareen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 29, 2025
Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS StudyCharles C Windon, Constantine Gatsonis, Maria C Carrillo, et al.
Radiology|September 5, 2018
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter TrialSavannah C Partridge, Zheng Zhang, David C Newitt, et al.
JAMA Network Open|May 10, 2022
Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)Soudabeh Fazeli, Bradley S Snyder, Ilana F Gareen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2019
Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702)Habib Rahbar, Zheng Zhang, Thomas L Chenevert, et al.
Pageof 4